JP2026016480A5 - - Google Patents

Info

Publication number
JP2026016480A5
JP2026016480A5 JP2025175127A JP2025175127A JP2026016480A5 JP 2026016480 A5 JP2026016480 A5 JP 2026016480A5 JP 2025175127 A JP2025175127 A JP 2025175127A JP 2025175127 A JP2025175127 A JP 2025175127A JP 2026016480 A5 JP2026016480 A5 JP 2026016480A5
Authority
JP
Japan
Prior art keywords
antigen
binding domain
bispecific antibody
heavy chain
hcvr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025175127A
Other languages
English (en)
Japanese (ja)
Other versions
JP2026016480A (ja
Filing date
Publication date
Priority claimed from JP2022535058A external-priority patent/JP7813703B2/ja
Application filed filed Critical
Publication of JP2026016480A publication Critical patent/JP2026016480A/ja
Publication of JP2026016480A5 publication Critical patent/JP2026016480A5/ja
Pending legal-status Critical Current

Links

JP2025175127A 2019-12-10 2025-10-17 抗cd20×抗cd3二重特異性抗体を含有する安定化製剤 Pending JP2026016480A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962946207P 2019-12-10 2019-12-10
US62/946,207 2019-12-10
JP2022535058A JP7813703B2 (ja) 2019-12-10 2020-12-09 抗cd20×抗cd3二重特異性抗体を含有する安定化製剤
PCT/US2020/064025 WO2021119135A1 (en) 2019-12-10 2020-12-09 Stabilized formulations containing anti-cd20 x anti-cd3 bispecific antibodies

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2022535058A Division JP7813703B2 (ja) 2019-12-10 2020-12-09 抗cd20×抗cd3二重特異性抗体を含有する安定化製剤

Publications (2)

Publication Number Publication Date
JP2026016480A JP2026016480A (ja) 2026-02-03
JP2026016480A5 true JP2026016480A5 (enExample) 2026-05-25

Family

ID=74141846

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022535058A Active JP7813703B2 (ja) 2019-12-10 2020-12-09 抗cd20×抗cd3二重特異性抗体を含有する安定化製剤
JP2025175127A Pending JP2026016480A (ja) 2019-12-10 2025-10-17 抗cd20×抗cd3二重特異性抗体を含有する安定化製剤

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2022535058A Active JP7813703B2 (ja) 2019-12-10 2020-12-09 抗cd20×抗cd3二重特異性抗体を含有する安定化製剤

Country Status (15)

Country Link
US (2) US20210206870A1 (enExample)
EP (1) EP4072585A1 (enExample)
JP (2) JP7813703B2 (enExample)
KR (1) KR20220113417A (enExample)
CN (1) CN115003331A (enExample)
AU (1) AU2020402030A1 (enExample)
BR (1) BR112022011150A2 (enExample)
CA (1) CA3161059A1 (enExample)
CL (3) CL2022001495A1 (enExample)
CO (1) CO2022008684A2 (enExample)
IL (1) IL293372A (enExample)
MY (1) MY210570A (enExample)
PH (1) PH12022551275A1 (enExample)
TW (1) TW202135860A (enExample)
WO (1) WO2021119135A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202400228A (zh) 2022-02-25 2024-01-01 美商再生元醫藥公司 減輕細胞激素釋放症候群的給藥方案

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0747045B2 (ja) 1986-10-15 1995-05-24 株式会社大協精工 積層した注射器用滑栓
JP3100727B2 (ja) 1992-01-23 2000-10-23 株式会社大協精工 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品
JP3172057B2 (ja) 1995-04-05 2001-06-04 株式会社大協精工 ラミネートゴム栓
JP3512349B2 (ja) 1999-01-29 2004-03-29 株式会社大協精工 柱状ゴム要素の成形型
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
JP2002209975A (ja) 2001-01-19 2002-07-30 Daikyo Seiko Ltd 医薬バイアル用ラミネートゴム栓
ES2537738T3 (es) * 2003-06-05 2015-06-11 Genentech, Inc. Terapia de combinación para trastornos de células B
EP2225275A4 (en) * 2007-11-28 2013-04-03 Medimmune Llc PROTEIN FORMULATION
JP2012041317A (ja) * 2010-08-23 2012-03-01 Panasonic Corp フェロセン修飾抗体
WO2012135408A1 (en) * 2011-03-31 2012-10-04 Merck Sharp & Dohme Corp. Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
HUE050159T2 (hu) * 2013-12-17 2020-11-30 Genentech Inc Anti-CD3 antitestek és alkalmazási eljárások
ES2809455T3 (es) * 2014-11-17 2021-03-04 Regeneron Pharma Métodos para tratamiento tumoral usando anticuerpo biespecífico CD3xCD20
CN108602889A (zh) * 2015-12-22 2018-09-28 瑞泽恩制药公司 医治急性成淋巴细胞性白血病的双特异性抗cd20/抗cd3抗体
TWI865430B (zh) * 2017-07-24 2024-12-11 美商再生元醫藥公司 穩定化之抗體組合物及其製法
MA49960A (fr) * 2017-08-25 2021-06-02 Omeros Corp Formulations d'anticorps inhibiteurs de masp-2 hautement concentrées à faible viscosité, kits et méthodes de traitement de sujets souffrant d'un syndrome hémolytique atypique
CA3202891A1 (en) * 2021-01-28 2022-08-04 Kara Olson Compositions and methods for treating cytokine release syndrome

Similar Documents

Publication Publication Date Title
JP2024016177A5 (enExample)
KR102359181B1 (ko) 항-rsv 모노클로날 항체 제제
RU2017107847A (ru) Стабильный состав на основе антитела к il-4r-альфа
JP2020518598A5 (enExample)
JP2025072446A (ja) モノクローナル抗体製剤
JP2020518600A5 (enExample)
JP2021512881A5 (enExample)
JP2018188437A5 (enExample)
RU2012131099A (ru) Препарат антитела
JP2022532927A5 (enExample)
RU2012133970A (ru) Стабилизированные составы, содержащие антитела к рецептору интерлейкина 6 (il-6r)
JP2022036932A5 (enExample)
JP2025090691A5 (enExample)
JP2020532562A5 (enExample)
JP2024138284A5 (enExample)
JP2024544523A5 (enExample)
JP2024540377A5 (enExample)
JP2024515968A5 (enExample)
JP2023518066A5 (enExample)
CN115803055A (zh) 一种抗pd-1单克隆抗体液体制剂
JP2022503886A5 (enExample)
AR129062A1 (es) Composiciones farmacéuticas de proteínas terapéuticas y métodos de uso
JP2020531523A5 (enExample)
RU2020111574A (ru) Высококонцентрированные, маловязкие препараты ингибирующих masp-2 антител, наборы и способы лечения субъектов, страдающих атипическим гемолитическим синдромом
JP2022529996A5 (enExample)